Sandbox fungal meningitis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 210: | Line 210: | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[albendazole]]''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[albendazole]]''''' | ||
|- | |- | ||
|} | |||
|} | |||
==M. tuberculosis Meningitis== | |||
{| | |||
|- | |||
| valign=top | | |||
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0"; | |||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[M. tuberculosis]]}}'' | |||
|-! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Intensive Phase(for 9-12 mo)'' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampicin]] 8-12 mg/kg/day PO max: 600mg''''' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Isoniazid]] 4-6 mg/kg/day PO max: 300mg''''' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Pyrazinamide]] 20-30 mg/kg/day PO''''' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Streptomycin]] 12-18 mg/kg/day PO''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Continuation Phase'' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampicin]] 8-12 mg/kg/day PO max: 600mg''''' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Isoniazid]] 4-6 mg/kg/day PO max: 300mg''''' | |||
|- | |||
|} | |||
|} | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} |
Revision as of 19:31, 22 January 2014
Meningitis Main Page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Sheng Shi, M.D. [2]
fungal meningitis
Blastomyces
|
Candidiasis
|
Histoplasma
|
Coccidioides[1]
|
Cryptococcus HIV/AIDS[2]
|
Cryptococcus Immunocompetent[3]
|
Viral Meningitis[4]
|
Parasitic Meningitis
Angiostrongyliasis
|
M. tuberculosis Meningitis
|
References
- ↑ Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA et al. (2005) Coccidioidomycosis. Clin Infect Dis 41 (9):1217-23. DOI:10.1086/496991 PMID: 16206093
- ↑ Antinori S (2013) New Insights into HIV/AIDS-Associated Cryptococcosis. ISRN AIDS 2013 ():471363.http://dx.doi.org/10.1155/2013/471363 DOI:10.1155/2013/471363] PMID: 24052889
- ↑ Jackson A, van der Horst C (2012) New insights in the prevention, diagnosis, and treatment of cryptococcal meningitis. Curr HIV/AIDS Rep 9 (3):267-77. DOI:10.1007/s11904-012-0127-7 PMID: 22763808
- ↑ Studahl M, Lindquist L, Eriksson BM, Günther G, Bengner M, Franzen-Röhl E et al. (2013) Acute viral infections of the central nervous system in immunocompetent adults: diagnosis and management. Drugs 73 (2):131-58. DOI:10.1007/s40265-013-0007-5 PMID: 23377760